Objective: To use clinical and spirometry findings in order to distinguish between the restrictive and nonspecific patterns of pulmonary function test results in patients with low FVC and a normal or elevated FEV1/FVC ratio.
Methods: We analyzed the pulmonary function test results of 211 adult patients submitted to spirometry and lung volume measurements. We used the clinical diagnosis at the time spirometry was ordered, together with various functional data, in order to distinguish between patients presenting with a "true" restrictive pattern (reduced TLC) and those presenting with a nonspecific pattern (normal TLC).
Results: In the study sample, TLC was reduced in 144 cases and was within the normal range in 67. The most common causes of a nonspecific pattern were obstructive disorders, congestive heart failure, obesity, bronchiolitis, interstitial diseases, and neuromuscular disorders. In patients given a working diagnosis of pulmonary fibrosis, pleural disease, or chest wall disease, the positive predictive value (PPV) for restriction was >or= 90%. In males, an FVC
Conclusions: In many patients with reduced FEV1, reduced FVC, and a normal FEV1/FVC ratio, the restrictive pattern can be identified with confidence through the use of an algorithm that takes the clinical diagnosis and certain spirometry measurements into account.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1590/s1806-37132010000400011 | DOI Listing |
Arch Microbiol
January 2025
Tecnológico Nacional de México, Instituto Tecnológico de Morelia, 58120, Morelia, Mexico.
The metabolites gluconic acid, 5-ketogluconic acid, proline, and glutamic acid, produced by Pseudomonas reptilivora B-6bs, are industrially important, particularly in food and pharmaceutical sectors. However, producing these metabolites involves biotin supplementation to enhance yields, which is an expensive additive, and reducing its use can significantly lower production costs. Thus, This study aimed to enhance the production of gluconic acid, 5-ketogluconic acid, proline, and glutamic acid without biotin supplementation.
View Article and Find Full Text PDFHell J Nucl Med
December 2024
Nuclear Medicine-PET/CT Department "Theageneio" Cancer Center, Thessaloniki, Greece.
Gallium-68-DOTA-D-phe1-try3-octreotide (Ga-DOTATOC) positron emission tomography/computed tomography (PET/CT) is a crucial diagnostic tool for neuroendocrine tumors (NET). Its accuracy is influenced by radiochemical purity and patient preparation. We present two cases where unexpected radiotracer uptake in Ga-DOTATOC PET/CT imaging was observed.
View Article and Find Full Text PDFFitoterapia
December 2024
Department of Chemistry, Universidade Tecnológica Federal do Paraná (UTFPR), Pato Branco, PR 85503-390, Brazil.
This study investigated the antihyperglycemic potential of a hydroalcoholic extract from Syzygium malaccense leaves (E-SM) and isolate phenolic compounds with antioxidant and cytotoxic activities through a bioguided assay. The aim was to explore the therapeutic properties of S. malaccense in managing hyperglycemia and oxidative stress-related conditions.
View Article and Find Full Text PDFAnal Chem
December 2024
Chinese Academy of Inspection and Quarantine, Beijing 100176, China.
Point-of-care testing (POCT) involves administering rapid on-site analysis to provide fast biochemical testing results. POCT reduces delays in clinical decision-making and eliminates the need to transport and prepare clinical samples for immediate diagnosis or clinical intervention by healthcare professionals. Herein, a novel methodology integrating thin-layer chromatography-based two-dimensional separation with miniature mass spectrometry was developed for rapid on-site clinical analysis.
View Article and Find Full Text PDFJ Neurosci Res
December 2024
National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy.
Niemann Pick type C1 (NPC1) is a rare, fatal disorder characterized by endosomal lipid accumulation that leads to damage of both peripheral organs and central nervous system (cerebellum and hippocampus are especially affected). Currently, miglustat is the only approved drug for NPC1, thus the identification of new treatments is mandatory. We have previously demonstrated that the drug dipyridamole (DIP), an enhancer of adenosine signaling, can reduce the pathological phenotype in patient-derived fibroblasts.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!